First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being…
Where health news comes full circle!